This ties in with the thread started by Tupelo3 last month.

A third clincal trial site for Nilotinib receives FDA approval

The strategy of Inhibikase Therapeutics makes sense to me. Their 6 month trial can determine efficacy sooner than the trial of MJFF et al. If the result is positive, they will have learned something useful (i.e. "(better understand) which patients with Parkinson's Disease are more likely to benefit from this (Abelson kinase inhibitor) therapy" ). Alternatively, if the result is negative, they can stop wasting money immediately.

As they say in their press release, they are developing two Abelson tyrosine kinase inhibitors that are as much as 60-times more potent than imatinib (Gleevec), and as much a 50-times more penetrant into the brain than nilotinib (Tasigna).